The story previously reported that the test being evaluated is from Rheonix and is based on its CARD technology. In fact, Mayo is developing its own test based on IP from Rheonix but not based on the CARD technology.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The Mayo Clinic said on Monday that it has reached an agreement with Rheonix to collaborate on evaluating the performance of a genotyping test for warfarin.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.